Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Invigor Medical vs Aurelius Health Group

Two GLP-1 desks, one scoreboard. We put Invigor Medical and Aurelius Health Group head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 9 · Grade B+

Invigor Medical

Visit Invigor Medical Full brief →
vs
No. 331 · Grade C

Aurelius Health Group

Visit Aurelius Health Group Full brief →

The verdict

Invigor Medical takes this head-to-head.

Invigor Medical scores 88 to 59 on our six-factor Brief Score — An established telehealth pharmacy with a broad metabolic and hormone catalog and a steady price line.

That doesn't make Aurelius Health Group a bad call — it's best for readers who want transparent, care-inclusive compounded tirzepatide microdosing. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
87
48
Supply Reliability
88
64
Transparency
84
72
Access Breadth
82
40
Clinical Oversight
88
76
Track Record
90
54
Invigor MedicalBrief Score 88 · 59Aurelius Health Group

Price, coverage & the tracker

Invigor MedicalAurelius Health Group
Brief Score88/100 (B+)59/100 (C)
Semaglutide$199/moNot disclosed
Tirzepatide$339/moFrom $89/mo (compounded)
CoverageNot disclosedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Invigor Medical: Long-running operator; mid-market pricing unchanged this cycle.

Aurelius Health Group: New to the tracker on 1 August 2026. The published line reads From $89/mo (compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.